Key result
Electrical carotid sinus stimulation reduced MSNA burst frequency similarly during hypoxia (-6.0 bursts/min) and hyperoxia (-4.5 bursts/min) in resistant hypertension.
Why the study?
The peripheral chemoreflex is tonically active in hypertensive patients and may inhibit baroreflex responses, prompting the hypothesis that peripheral chemoreflex activation attenuates baroreflex efficacy evoked by electrical carotid sinus stimulation.
Does peripheral chemoreflex activation attenuate the efficacy of electrical baroreflex activation in patients with resistant hypertension?
RCT (n=11)
Single-blind
1:1
Yes
Does peripheral chemoreflex activation attenuate the efficacy of electrical baroreflex activation in patients with resistant hypertension?
Absolute Event Rate: -6% vs -4.5%
p-value: p=0.531
Moderate peripheral chemoreflex activation does not attenuate the acute blood pressure and sympathetic nerve activity reductions achieved by electrical baroreflex activation therapy in patients with resistant hypertension.
Moderate chemoreflex activation does not attenuate acute effects of carotid sinus stimulation; leaves open durability of baroreflex therapy in resistant hypertension.
Arterial baroreflex activation through electrical carotid sinus stimulation has been developed for the treatment of resistant hypertension. Previous studies suggested that the peripheral chemoreflex is tonically active in hypertensive patients and may inhibit baroreflex responses. We hypothesized that peripheral chemoreflex activation attenuates baroreflex efficacy evoked by electrical carotid sinus stimulation. We screened 35 patients with an implanted electrical carotid sinus stimulator. Of those, 11 patients with consistent acute depressor response were selected (7 men/4 women, age: 67±8 years, body mass index: 31.6±5.2 kg/m 2 , 6±2 antihypertensive drug classes). We assessed responses to electrical baroreflex stimulation during normoxia, isocapnic hypoxia (SpO 2 : 79.0±1.5%), and hyperoxia (40% end-tidal O 2 fraction) by measuring heart rate, blood pressure, ventilation, oxygen saturation, end-tidal CO 2 and O 2 fractions, and muscle sympathetic nerve activity. During normoxia, baroreflex activation reduced systolic blood pressure from 164±27 to 151±25 mm Hg (mean±SD, P <0.001), heart rate from 64±13 to 61±13 bpm ( P =0.002), and muscle sympathetic nerve activity from 42±12 to 36±12 bursts/min ( P =0.004). Hypoxia increased systolic blood pressure 8±12 mm Hg ( P =0.057), heart rate 10±6 bpm ( P <0.001), muscle sympathetic nerve activity 7±7 bursts/min ( P =0.031), and ventilation 10±7 L/min ( P =0.002). However, responses to electrical carotid sinus stimulation did not differ between hypoxic and hyperoxic conditions: systolic blood pressure: −15±7 versus −14±8 mm Hg ( P =0.938), heart rate: −2±3 versus −2±2 bpm ( P =0.701), and muscle sympathetic nerve activity: −6±4 versus −4±3 bursts/min ( P =0.531). We conclude that moderate peripheral chemoreflex activation does not attenuate acute responses to electrical baroreflex activation therapy in patients with resistant hypertension. These patients provided insight into human baroreflex-chemoreflex interactions that could not be gained otherwise.
No takes yet. Share an insight, caveat, or question.
Heusser et al. (2019) conducted an RCT in Resistant hypertension (n=11). Electrical carotid sinus stimulation during isocapnic hypoxia vs. Electrical carotid sinus stimulation during hyperoxia was evaluated on Difference in MSNA burst frequency with electrical carotid sinus stimulation during hypoxia versus hyperoxia (p=0.531). Electrical carotid sinus stimulation reduced MSNA burst frequency similarly during hypoxia (-6.0 bursts/min) and hyperoxia (-4.5 bursts/min) in resistant hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: